Redwood City, Calif.-based Coherus Biosciences Inc. said August Troendle resigned from the company's board.
In order to balance the membership among the company's three director classes following Troendle's resignation, V. Bryan Lawlis was reclassified as a class 1 director from class 2 director previously.
Lawlis' reappointment decreases the number of Coherus' authorized directors from eight to seven.
Coherus Biosciences develops biosimilars for treating arthritis, cancers and other diseases. The company noted that Troendle's resignation was not as a result of any disagreement.
